Skip to main content
. 2023 Feb 27;13:3347. doi: 10.1038/s41598-023-29630-9

Table 4.

Immune Assays.

Study DTH/ELISPOT assays ICS Other immune assays? Phenotypic analysis?
Assay Stimulus Positive responses? Correlation with clinical outcomes?

Oh (2020)

Oh (2016)

ELISPOT Whole Cell Yes NR No No No
Bota (2018) Neither NA NA NA No CD3/CD4 + count; maximal and end of treatment Yes
Schulze (2009) Neither NA NA NA No No No
Peng (2006) DTH Lysate Yes Yes No No No
Uyl-de Groot (2005), Vermorken (1999) DTH Whole Cell No NA No No No
Peng (2005) DTH Lysate Yes Yes No Flow cytometry; proportion of CD3, CD4, CD8, CD16, and CD56 positive cells Yes
Kuang (2004) DTH Lysate Yes Yes No No No
Harris (2000) DTH Whole Cell Yes Yes No No No
Galligioni (1996) DTH Whole Cell Yes NR No No No
Hoover (1993) DTH Whole Cell Yes NR No No No
Gray (1989, 1988) Neither NA NA NA No No No
Adler (1987) DTH Whole Cell Yes Yes No In vitro lymphocyte stimulation, immune response to tuberculin No
Souter (1981) Neither NA NA NA No No No
Embleton (1978), McIllmurray (1977) Neither NA NA NA No In vitro cytotoxicity and leukocyte responses to stimulants PHA, PWM, ConA No

DTH delayed type hypersensitivity, ICS intracellular cytokine staining, ELISPOT enzyme linked immunospot, NR not reported, NA not applicable, PHA phytohaemagglutinin, PMW pokeweed mitogen, ConA concanavalin A.